AR066290A1 - Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso - Google Patents
Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su usoInfo
- Publication number
- AR066290A1 AR066290A1 ARP080101740A ARP080101740A AR066290A1 AR 066290 A1 AR066290 A1 AR 066290A1 AR P080101740 A ARP080101740 A AR P080101740A AR P080101740 A ARP080101740 A AR P080101740A AR 066290 A1 AR066290 A1 AR 066290A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkyloxy
- dialkylamino
- alkylamino
- carbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos resultan adecuados, por ejemplo, para el tratamiento del síndrome metabolico, la resistencia a la insulina, la obesidad y la diabetes. Reivindicacion 1.- Un compuesto de formula 1, en a que R es hidrogeno, alquilo(C1-16),alquiloxi(C1-5), alquiltio(C1-5), alquamino(C1-5), dialquilamino(C2-8), (alquilen(C0-4))arilo(C6-C10), (alquilen(C0-C4))heteroarilo(C5-12), (alquilen(C0-4))heterociclilo(C3-12) (alquilen(C0-4))cicloalquilo(C3-12), un sistema de anillos (C8-14)bicíclico, en la que arilo, heteroarilo, heterociclilo, cicloalquilo o el sistema de anillos (C8-14) bicíclico puede estar mono- o polisustituido con halogeno, alquilo(C1-6), alquiloxi(C1-3), hidroxilo, alquilmercapto(C1-6), amino, alquilamino(C1-6), dialquilamino(C2-12), (monoalquilamino(C1-6))carbonilo, (dialquilamino(C2-8))carbonilo, (alcoxi(C1-6))carbonilo, (alquil(C1-6))carbonilo, ciano, trifluorometilo, trifluorometiloxi, alquilsulfonilo(C1-6), o aminosulfonilo; R1 es hidrogeno,alquilo(C1-10), alquiloxi(C1-10), amino, monoalquilamino(C1-10), dialquilamino(C2-12), en la que alquilo puede estar sustituido con halogeno, alquilo(C1-6), alquiloxi(C1-3), hidroxilo, alquilmercapto(C1-6), amino, alquilamino(C1-6), dialquilamino(C2-12), arilo(C6-10), heteroarilo(C5-12), heterocicIiIo(C3-12) o cicloaIquilo(C3-12), en la que arilo, heteroarilo, heterociclilo o cicloalquilo pueden estar cada uno opcionalmente mono- o polisustituidos con halogeno, alquilo(C1-6), alquiloxi(C1-3),hidroxilo, alquilmercapto(C1-6), amino, alquilamino(C1-6), diaIquiIamino(C2-12); R2 es hidrogeno, alquilo(C1-16), (alquilen(C0-4))arilo(C6-C10); R3 es hidrogeno, alquilo(C1-6), alquiloxi(C1-3), hidroxilo, alquilmercapto(C1-6), amino, alquilamino(C1-6), dialquilamino(C2-12), ciano, (alquil(C1-6))carbonilo, halogeno, trifluorometilo, trifluorometiloxi, alquilsulfonilo(C1-6), aminosulfonilo; A es O, S, N(R2), C(R3), C(R3)=C(R3), NH=C(R3), C(R3)=NH, NH=NH; B es C(R3), N(R2); D es C(R3), N(R2); enla que al menos uno de los miembros de A, B o D debe ser nitrogeno; n son cada uno independientemente 1 o 2; L es un enlace; -C(=O)-, -C(=S)-, -C(=O)-N(R2)-, -C(=O)-O-, -S(O)0-2-, -S(O)0-2-N(R2)-,un sistema de anillos mono- o bicíclico en el que unoo más miembros del anillo pueden ser N(R3), O, S o -C(=O)-; M es -C(=O)-N(R2)-, -N(R2)-C(=O)-, -S(O)0-2-, -S(O)0-2-N(R2)-, -N(R2)-S(O)0-2- , -C(=O)-O-, -O-C(=O)-; y sus sales fisiologicamente compatibles.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07008646 | 2007-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066290A1 true AR066290A1 (es) | 2009-08-12 |
Family
ID=38473076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101740A AR066290A1 (es) | 2007-04-27 | 2008-04-24 | Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8003677B2 (es) |
| EP (1) | EP2152711B1 (es) |
| JP (1) | JP2010524987A (es) |
| KR (1) | KR20100015975A (es) |
| CN (1) | CN101663306A (es) |
| AR (1) | AR066290A1 (es) |
| AT (1) | ATE489389T1 (es) |
| AU (1) | AU2008248996A1 (es) |
| BR (1) | BRPI0810858A2 (es) |
| CA (1) | CA2685543A1 (es) |
| CL (1) | CL2008001215A1 (es) |
| DE (1) | DE502008001903D1 (es) |
| IL (1) | IL201764A0 (es) |
| MX (1) | MX2009011112A (es) |
| TW (1) | TW200911809A (es) |
| UY (1) | UY31053A1 (es) |
| WO (1) | WO2008135141A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010028761A1 (de) * | 2008-09-09 | 2010-03-18 | Sanofi-Aventis | 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren |
| US20120010186A1 (en) * | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| PL2521450T3 (pl) | 2010-01-07 | 2015-07-31 | Du Pont | Grzybobójcze związki heterocykliczne |
| CN102260265B (zh) * | 2010-05-24 | 2015-09-02 | 上海阳帆医药科技有限公司 | 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途 |
| US20130197043A1 (en) | 2010-08-31 | 2013-08-01 | Snu R&Db Foundation | Use of the fetal reprogramming of a ppar agonist |
| US8501768B2 (en) * | 2011-05-17 | 2013-08-06 | Hoffmann-La Roche Inc. | Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds |
| EP2766000A2 (en) | 2011-10-15 | 2014-08-20 | F.Hoffmann-La Roche Ag | Scd1 antagonists for treating cancer |
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| LT2900669T (lt) | 2012-09-25 | 2019-11-11 | Hoffmann La Roche | Heksahidropirol[3,4-c]pirolo dariniai ir susiję junginai kaip autotaksino (atx) inhibitoriai ir kaip lizofosfatidinės rūgšties (lpa) gamybos inhibitoriai, skirti gydyti pvz., inkstų ligas |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| CA2923523A1 (en) | 2013-11-26 | 2015-06-04 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl |
| MX2016010675A (es) | 2014-03-26 | 2016-11-10 | Hoffmann La Roche | Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa). |
| UA118582C2 (uk) | 2014-03-26 | 2019-02-11 | Ф. Хоффманн-Ля Рош Аг | Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa) |
| WO2016046837A1 (en) | 2014-09-22 | 2016-03-31 | Cadila Healthcare Limited | An improved process for preparation of pyrrolo[3,4- c] pyrrole compounds and intermediates thereof |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| WO2017037146A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| AU2016328436B2 (en) * | 2015-09-24 | 2020-05-14 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| CA2991615A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| CN108299437B (zh) * | 2017-01-13 | 2022-07-08 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
| CN110392679B (zh) | 2017-03-16 | 2023-04-07 | 豪夫迈·罗氏有限公司 | 可用作双重atx/ca抑制剂的杂环化合物 |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| HUE049979T2 (hu) | 2017-03-20 | 2020-11-30 | Forma Therapeutics Inc | Pirrolopirrol készítmények piruvát-kináz (PKR) aktivátorokként |
| BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
| CN113226356A (zh) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | 活化丙酮酸激酶r |
| WO2024112764A1 (en) | 2022-11-21 | 2024-05-30 | Novo Nordisk Health Care Ag | Synthesis of pyrrolo[3,4-c]pyrroles |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0515483A (pt) * | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
| EP1804799B1 (en) * | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
-
2008
- 2008-04-16 WO PCT/EP2008/003019 patent/WO2008135141A1/de active Application Filing
- 2008-04-16 DE DE502008001903T patent/DE502008001903D1/de active Active
- 2008-04-16 BR BRPI0810858-7A2A patent/BRPI0810858A2/pt not_active Application Discontinuation
- 2008-04-16 CN CN200880012991A patent/CN101663306A/zh active Pending
- 2008-04-16 AT AT08735269T patent/ATE489389T1/de active
- 2008-04-16 JP JP2010504505A patent/JP2010524987A/ja not_active Withdrawn
- 2008-04-16 AU AU2008248996A patent/AU2008248996A1/en not_active Abandoned
- 2008-04-16 CA CA002685543A patent/CA2685543A1/en not_active Abandoned
- 2008-04-16 MX MX2009011112A patent/MX2009011112A/es not_active Application Discontinuation
- 2008-04-16 KR KR1020097022497A patent/KR20100015975A/ko not_active Application Discontinuation
- 2008-04-16 EP EP08735269A patent/EP2152711B1/de not_active Not-in-force
- 2008-04-24 AR ARP080101740A patent/AR066290A1/es unknown
- 2008-04-24 TW TW097114960A patent/TW200911809A/zh unknown
- 2008-04-25 CL CL200801215A patent/CL2008001215A1/es unknown
- 2008-04-25 UY UY31053A patent/UY31053A1/es not_active Application Discontinuation
-
2009
- 2009-10-26 IL IL201764A patent/IL201764A0/en unknown
- 2009-10-26 US US12/605,631 patent/US8003677B2/en not_active Expired - Fee Related
-
2011
- 2011-06-15 US US13/160,705 patent/US20110245263A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110245263A1 (en) | 2011-10-06 |
| WO2008135141A1 (de) | 2008-11-13 |
| AU2008248996A1 (en) | 2008-11-13 |
| CA2685543A1 (en) | 2008-11-13 |
| CL2008001215A1 (es) | 2008-09-22 |
| EP2152711A1 (de) | 2010-02-17 |
| US8003677B2 (en) | 2011-08-23 |
| ATE489389T1 (de) | 2010-12-15 |
| UY31053A1 (es) | 2008-11-28 |
| DE502008001903D1 (de) | 2011-01-05 |
| CN101663306A (zh) | 2010-03-03 |
| EP2152711B1 (de) | 2010-11-24 |
| TW200911809A (en) | 2009-03-16 |
| US20100144594A1 (en) | 2010-06-10 |
| IL201764A0 (en) | 2010-06-16 |
| KR20100015975A (ko) | 2010-02-12 |
| BRPI0810858A2 (pt) | 2014-10-29 |
| MX2009011112A (es) | 2009-10-28 |
| JP2010524987A (ja) | 2010-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066290A1 (es) | Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso | |
| AR073499A1 (es) | Derivados de 2-heteroaril-pirrolo[3,4-c]pirrolo, procesos para su preparacion, medicamentos que comprenden dichos compuestos y su uso como inhibidor de scd" | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR079510A1 (es) | Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central. | |
| AR066659A1 (es) | Derivados de espiroindolinona | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR075111A1 (es) | Derivados heterociclicos de diazoles y triazoles, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del metabolismo y del sistema nervioso, entre otros. | |
| AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
| AR054529A1 (es) | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 | |
| PE20120034A1 (es) | Compuestos derivados de n-fenilpirimidin-2-amina | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20090770A1 (es) | Derivados de benzoxazolona | |
| AR050698A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| PE20070002A1 (es) | Compuestos derivados de heteroaril como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo i | |
| AR055620A1 (es) | Derivados de cicloalcano-carboxamidas | |
| AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. | |
| AR081315A1 (es) | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t | |
| AR055016A1 (es) | Aminoalcoholes triciclicos, procedimientos para su preparacion y su uso para la preparacion de medicamentos | |
| AR068014A1 (es) | Derivados de pirimidin-2-il-amina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la cinasa. | |
| AR075597A1 (es) | Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas . | |
| PE20090068A1 (es) | Compuestos de anillo fusionado como agonistas parciales de ppar gamma | |
| UY28764A1 (es) | Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico | |
| NO20091893L (no) | Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |